The abstract is read at the publisher; the summary is JClub's.
In Th3 mouse models of non-transfusion-dependent β-thalassemia, Tmprss6 antisense oligonucleotides increased phospho-Smad1/5/8 and hepcidin and improved iron outcomes, but failed in ERFE-overexpressing Th3 mice.
- Why it matters: Human NTDT trials show limited benefit from anti-TMPRSS6 therapy, and resistance may relate to high ERFE and severe iron overload that can alter hepatic BMP/Smad signaling.
- What they did: ERFE-overexpressing Th3 mice (T-E(M)) and littermates were treated with Tmprss6 ASO or nontargeting ASO for 4 weeks, and C57BL/6 mice were also challenged with 10 mg iron dextran or 5000 ppm high-iron diet.
- The result: In Th3 mice, Tmprss6 ASO raised phospho-Smad1/5/8 and hepcidin and improved splenomegaly, extramedullary erythropoiesis, and iron parameters, but showed no further hepcidin/phospho-Smad increase or erythroid/iron improvements in ERFE-overexpressing or iron-overloaded mice.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.